Core Insights - Wanbangde (002082.SZ) is advancing new drug development projects in the field of amyotrophic lateral sclerosis (ALS) and has secured core patent authorization for a differentiated MCR cyclic peptide in the metabolic field [1] Group 1 - The company has laid out new drug research projects specifically targeting ALS [1] - Wanbangde has achieved core patent authorization for its differentiated MCR cyclic peptide [1] - Both the ALS and metabolic projects are progressing steadily [1]

Core Viewpoint - Wanbangde (002082.SZ) is advancing its differentiated MCR cyclic peptide new drug in the metabolism field and has obtained core patent authorization, while also developing new drug projects in the field of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The company has made significant progress in the metabolism sector with the development of a differentiated MCR cyclic peptide new drug [1] - Core patent authorization has been successfully obtained for the new drug in the metabolism field [1] - In the ALS sector, the company is actively pursuing new drug research and development projects [1]